APO Research
Talk to an analyst

APO RESEARCH · REPORT

T Cell Surface Glycoprotein CD4

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global T Cell Surface Glycoprotein CD4 Market Outlook and Growth Opportunities 2026

19 December 2025192 pages

Choose your research edition.

Industry ResearchT Cell Surface Glycoprotein CD4 Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal T Cell Surface Glycoprotein CD4 Industry Growth and Trends Forecast to 203290 pages · $3,450 USDMarket StructureGlobal T Cell Surface Glycoprotein CD4 Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032180 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal T Cell Surface Glycoprotein CD4 Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal T Cell Surface Glycoprotein CD4 Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global T Cell Surface Glycoprotein CD4 market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for T Cell Surface Glycoprotein CD4 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for T Cell Surface Glycoprotein CD4 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for T Cell Surface Glycoprotein CD4 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the T Cell Surface Glycoprotein CD4 market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the T Cell Surface Glycoprotein CD4 market include Sanofi, United Biomedical Inc, Bristol-Myers Squibb Co, TaiMed Biologics Inc, Immupharma Plc, Fountain Biopharma Inc, CEL-SCI Corp and Biotest AG, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global T Cell Surface Glycoprotein CD4 market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of T Cell Surface Glycoprotein CD4 and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents T Cell Surface Glycoprotein CD4 sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the T Cell Surface Glycoprotein CD4 market size, projected growth trends, production technologies, key applications, and end-use industries.

T Cell Surface Glycoprotein CD4 Segment by Company

Sanofi

United Biomedical Inc

Bristol-Myers Squibb Co

TaiMed Biologics Inc

Immupharma Plc

Fountain Biopharma Inc

CEL-SCI Corp

Biotest AG

T Cell Surface Glycoprotein CD4 Segment by Type

Forigerimod Acetate

Ibalizumab

HIV Vaccine 2

Others

T Cell Surface Glycoprotein CD4 Segment by Application

HIV

GVHD

SARS

AIDS

Others

T Cell Surface Glycoprotein CD4 Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global T Cell Surface Glycoprotein CD4 status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions T Cell Surface Glycoprotein CD4 market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify T Cell Surface Glycoprotein CD4 significant trends, drivers, influence factors in global and regions.

6. To analyze T Cell Surface Glycoprotein CD4 competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global T Cell Surface Glycoprotein CD4 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of T Cell Surface Glycoprotein CD4 and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of T Cell Surface Glycoprotein CD4.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the T Cell Surface Glycoprotein CD4 market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global T Cell Surface Glycoprotein CD4 industry.

Chapter 3: Detailed analysis of T Cell Surface Glycoprotein CD4 manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of T Cell Surface Glycoprotein CD4 in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of T Cell Surface Glycoprotein CD4 in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. T Cell Surface Glycoprotein CD4 Industry Trends Table 2. T Cell Surface Glycoprotein CD4 Industry Drivers Table 3. T Cell Surface Glycoprotein CD4 Industry Opportunities and Challenges Table 4. T Cell Surface Glycoprotein CD4 Industry Restraints Table 5. Global T Cell Surface Glycoprotein CD4 Revenue by Company (US$ Million) & (2021-2026) Table 6. Global T Cell Surface Glycoprotein CD4 Revenue Share by Company (2021-2026) Table 7. Global T Cell Surface Glycoprotein CD4 Sales Volume by Company (K Units) & (2021-2026) Table 8. Global T Cell Surface Glycoprotein CD4 Sales Volume Share by Company (2021-2026) Table 9. Global T Cell Surface Glycoprotein CD4 Average Price (US$/Unit) of Company (2021-2026) Table 10. Global T Cell Surface Glycoprotein CD4 Company Ranking, (2024-2026) & (USD Million) Table 11. Global T Cell Surface Glycoprotein CD4 Key Company Manufacturing Base & Headquarters Table 12. Global T Cell Surface Glycoprotein CD4 Company, Product Type & Application Table 13. Global T Cell Surface Glycoprotein CD4 Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global T Cell Surface Glycoprotein CD4 by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Forigerimod Acetate Table 18. Significant Companies of Ibalizumab Table 19. Significant Companies of HIV Vaccine 2 Table 20. Significant Companies of Others Table 21. Global T Cell Surface Glycoprotein CD4 Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global T Cell Surface Glycoprotein CD4 Sales Volume by Type (2021-2026) & (K Units) Table 23. Global T Cell Surface Glycoprotein CD4 Sales Volume by Type (2027-2032) & (K Units) Table 24. Global T Cell Surface Glycoprotein CD4 Sales Volume Share by Type (2021-2026) Table 25. Global T Cell Surface Glycoprotein CD4 Sales Volume Share by Type (2027-2032) Table 26. Global T Cell Surface Glycoprotein CD4 Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global T Cell Surface Glycoprotein CD4 Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global T Cell Surface Glycoprotein CD4 Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global T Cell Surface Glycoprotein CD4 Sales Value Share by Type (2021-2026) Table 30. Global T Cell Surface Glycoprotein CD4 Sales Value Share by Type (2027-2032) Table 31. Significant Companies of HIV Table 32. Significant Companies of GVHD Table 33. Significant Companies of SARS Table 34. Significant Companies of AIDS Table 35. Significant Companies of Others Table 36. Global T Cell Surface Glycoprotein CD4 Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global T Cell Surface Glycoprotein CD4 Sales Volume by Application (2021-2026) & (K Units) Table 38. Global T Cell Surface Glycoprotein CD4 Sales Volume by Application (2027-2032) & (K Units) Table 39. Global T Cell Surface Glycoprotein CD4 Sales Volume Share by Application (2021-2026) Table 40. Global T Cell Surface Glycoprotein CD4 Sales Volume Share by Application (2027-2032) Table 41. Global T Cell Surface Glycoprotein CD4 Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 42. Global T Cell Surface Glycoprotein CD4 Sales Value by Application (2021-2026) & (US$ Million) Table 43. Global T Cell Surface Glycoprotein CD4 Sales Value by Application (2027-2032) & (US$ Million) Table 44. Global T Cell Surface Glycoprotein CD4 Sales Value Share by Application (2021-2026) Table 45. Global T Cell Surface Glycoprotein CD4 Sales Value Share by Application (2027-2032) Table 46. Global T Cell Surface Glycoprotein CD4 Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 47. Global T Cell Surface Glycoprotein CD4 Sales by Region (2021-2026) & (K Units) Table 48. Global T Cell Surface Glycoprotein CD4 Sales Market Share by Region (2021-2026) Table 49. Global T Cell Surface Glycoprotein CD4 Sales by Region (2027-2032) & (K Units) Table 50. Global T Cell Surface Glycoprotein CD4 Sales Market Share by Region (2027-2032) Table 51. Global T Cell Surface Glycoprotein CD4 Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 52. Global T Cell Surface Glycoprotein CD4 Sales Value by Region (2021-2026) & (US$ Million) Table 53. Global T Cell Surface Glycoprotein CD4 Sales Value Share by Region (2021-2026) Table 54. Global T Cell Surface Glycoprotein CD4 Sales Value by Region (2027-2032) & (US$ Million) Table 55. Global T Cell Surface Glycoprotein CD4 Sales Value Share by Region (2027-2032) Table 56. Global T Cell Surface Glycoprotein CD4 Market Average Price (US$/Unit) by Region (2021-2026) Table 57. Global T Cell Surface Glycoprotein CD4 Market Average Price (US$/Unit) by Region (2027-2032) Table 58. Global T Cell Surface Glycoprotein CD4 Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 59. Global T Cell Surface Glycoprotein CD4 Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global T Cell Surface Glycoprotein CD4 Sales by Country (2021-2026) & (K Units) Table 61. Global T Cell Surface Glycoprotein CD4 Sales Market Share by Country (2021-2026) Table 62. Global T Cell Surface Glycoprotein CD4 Sales by Country (2027-2032) & (K Units) Table 63. Global T Cell Surface Glycoprotein CD4 Sales Market Share by Country (2027-2032) Table 64. Global T Cell Surface Glycoprotein CD4 Sales Value by Country (2021-2026) & (US$ Million) Table 65. Global T Cell Surface Glycoprotein CD4 Sales Value Market Share by Country (2021-2026) Table 66. Global T Cell Surface Glycoprotein CD4 Sales Value by Country (2027-2032) & (US$ Million) Table 67. Global T Cell Surface Glycoprotein CD4 Sales Value Market Share by Country (2027-2032) Table 68. Sanofi Company Information Table 69. Sanofi Business Overview Table 70. Sanofi T Cell Surface Glycoprotein CD4 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Sanofi T Cell Surface Glycoprotein CD4 Product Portfolio Table 72. Sanofi Recent Development Table 73. United Biomedical Inc Company Information Table 74. United Biomedical Inc Business Overview Table 75. United Biomedical Inc T Cell Surface Glycoprotein CD4 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. United Biomedical Inc T Cell Surface Glycoprotein CD4 Product Portfolio Table 77. United Biomedical Inc Recent Development Table 78. Bristol-Myers Squibb Co Company Information Table 79. Bristol-Myers Squibb Co Business Overview Table 80. Bristol-Myers Squibb Co T Cell Surface Glycoprotein CD4 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Bristol-Myers Squibb Co T Cell Surface Glycoprotein CD4 Product Portfolio Table 82. Bristol-Myers Squibb Co Recent Development Table 83. TaiMed Biologics Inc Company Information Table 84. TaiMed Biologics Inc Business Overview Table 85. TaiMed Biologics Inc T Cell Surface Glycoprotein CD4 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. TaiMed Biologics Inc T Cell Surface Glycoprotein CD4 Product Portfolio Table 87. TaiMed Biologics Inc Recent Development Table 88. Immupharma Plc Company Information Table 89. Immupharma Plc Business Overview Table 90. Immupharma Plc T Cell Surface Glycoprotein CD4 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Immupharma Plc T Cell Surface Glycoprotein CD4 Product Portfolio Table 92. Immupharma Plc Recent Development Table 93. Fountain Biopharma Inc Company Information Table 94. Fountain Biopharma Inc Business Overview Table 95. Fountain Biopharma Inc T Cell Surface Glycoprotein CD4 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Fountain Biopharma Inc T Cell Surface Glycoprotein CD4 Product Portfolio Table 97. Fountain Biopharma Inc Recent Development Table 98. CEL-SCI Corp Company Information Table 99. CEL-SCI Corp Business Overview Table 100. CEL-SCI Corp T Cell Surface Glycoprotein CD4 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. CEL-SCI Corp T Cell Surface Glycoprotein CD4 Product Portfolio Table 102. CEL-SCI Corp Recent Development Table 103. Biotest AG Company Information Table 104. Biotest AG Business Overview Table 105. Biotest AG T Cell Surface Glycoprotein CD4 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Biotest AG T Cell Surface Glycoprotein CD4 Product Portfolio Table 107. Biotest AG Recent Development Table 108. Key Raw Materials Table 109. Raw Materials Key Suppliers Table 110. T Cell Surface Glycoprotein CD4 Distributors List Table 111. T Cell Surface Glycoprotein CD4 Customers List Table 112. Research Programs/Design for This Report Table 113. Authors List of This Report Table 114. Secondary Sources Table 115. Primary Sources List of Figures Figure 1. T Cell Surface Glycoprotein CD4 Product Image Figure 2. Global T Cell Surface Glycoprotein CD4 Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global T Cell Surface Glycoprotein CD4 Sales Value (2021-2032) & (US$ Million) Figure 4. Global T Cell Surface Glycoprotein CD4 Sales (2021-2032) & (K Units) Figure 5. Global T Cell Surface Glycoprotein CD4 Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global T Cell Surface Glycoprotein CD4 Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Forigerimod Acetate Image Figure 10. Ibalizumab Image Figure 11. HIV Vaccine 2 Image Figure 12. Others Image Figure 13. Global T Cell Surface Glycoprotein CD4 Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global T Cell Surface Glycoprotein CD4 Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global T Cell Surface Glycoprotein CD4 Sales Volume Share by Type (2021-2032) Figure 16. Global T Cell Surface Glycoprotein CD4 Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global T Cell Surface Glycoprotein CD4 Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global T Cell Surface Glycoprotein CD4 Sales Value Share by Type (2021-2032) Figure 19. HIV Image Figure 20. GVHD Image Figure 21. SARS Image Figure 22. AIDS Image Figure 23. Others Image Figure 24. Global T Cell Surface Glycoprotein CD4 Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global T Cell Surface Glycoprotein CD4 Sales Volume Share 2021 VS 2025 VS 2032 Figure 26. Global T Cell Surface Glycoprotein CD4 Sales Volume Share by Application (2021-2032) Figure 27. Global T Cell Surface Glycoprotein CD4 Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global T Cell Surface Glycoprotein CD4 Sales Value Share 2021 VS 2025 VS 2032 Figure 29. Global T Cell Surface Glycoprotein CD4 Sales Value Share by Application (2021-2032) Figure 30. Global T Cell Surface Glycoprotein CD4 Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 31. Global T Cell Surface Glycoprotein CD4 Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 32. Global T Cell Surface Glycoprotein CD4 Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 33. Global T Cell Surface Glycoprotein CD4 Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 34. North America T Cell Surface Glycoprotein CD4 Sales Value (2021-2032) & (US$ Million) Figure 35. North America T Cell Surface Glycoprotein CD4 Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Europe T Cell Surface Glycoprotein CD4 Sales Value (2021-2032) & (US$ Million) Figure 37. Europe T Cell Surface Glycoprotein CD4 Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Asia-Pacific T Cell Surface Glycoprotein CD4 Sales Value (2021-2032) & (US$ Million) Figure 39. Asia-Pacific T Cell Surface Glycoprotein CD4 Sales Value Share by Country (%), 2025 VS 2032 Figure 40. South America T Cell Surface Glycoprotein CD4 Sales Value (2021-2032) & (US$ Million) Figure 41. South America T Cell Surface Glycoprotein CD4 Sales Value Share by Country (%), 2025 VS 2032 Figure 42. Middle East & Africa T Cell Surface Glycoprotein CD4 Sales Value (2021-2032) & (US$ Million) Figure 43. Middle East & Africa T Cell Surface Glycoprotein CD4 Sales Value Share by Country (%), 2025 VS 2032 Figure 44. USA T Cell Surface Glycoprotein CD4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. USA T Cell Surface Glycoprotein CD4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. USA T Cell Surface Glycoprotein CD4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Canada T Cell Surface Glycoprotein CD4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Canada T Cell Surface Glycoprotein CD4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Canada T Cell Surface Glycoprotein CD4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Mexico T Cell Surface Glycoprotein CD4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Mexico T Cell Surface Glycoprotein CD4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Mexico T Cell Surface Glycoprotein CD4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Germany T Cell Surface Glycoprotein CD4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Germany T Cell Surface Glycoprotein CD4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Germany T Cell Surface Glycoprotein CD4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. France T Cell Surface Glycoprotein CD4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. France T Cell Surface Glycoprotein CD4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. France T Cell Surface Glycoprotein CD4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. U.K. T Cell Surface Glycoprotein CD4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. U.K. T Cell Surface Glycoprotein CD4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. U.K. T Cell Surface Glycoprotein CD4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Italy T Cell Surface Glycoprotein CD4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Italy T Cell Surface Glycoprotein CD4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Italy T Cell Surface Glycoprotein CD4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Spain T Cell Surface Glycoprotein CD4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Spain T Cell Surface Glycoprotein CD4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Spain T Cell Surface Glycoprotein CD4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Russia T Cell Surface Glycoprotein CD4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Russia T Cell Surface Glycoprotein CD4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Russia T Cell Surface Glycoprotein CD4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Netherlands T Cell Surface Glycoprotein CD4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Netherlands T Cell Surface Glycoprotein CD4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Netherlands T Cell Surface Glycoprotein CD4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Nordic Countries T Cell Surface Glycoprotein CD4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Nordic Countries T Cell Surface Glycoprotein CD4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Nordic Countries T Cell Surface Glycoprotein CD4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. China T Cell Surface Glycoprotein CD4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. China T Cell Surface Glycoprotein CD4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. China T Cell Surface Glycoprotein CD4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Japan T Cell Surface Glycoprotein CD4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Japan T Cell Surface Glycoprotein CD4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Japan T Cell Surface Glycoprotein CD4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. South Korea T Cell Surface Glycoprotein CD4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. South Korea T Cell Surface Glycoprotein CD4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. South Korea T Cell Surface Glycoprotein CD4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. India T Cell Surface Glycoprotein CD4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. India T Cell Surface Glycoprotein CD4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. India T Cell Surface Glycoprotein CD4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Australia T Cell Surface Glycoprotein CD4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Australia T Cell Surface Glycoprotein CD4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Australia T Cell Surface Glycoprotein CD4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Southeast Asia T Cell Surface Glycoprotein CD4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Southeast Asia T Cell Surface Glycoprotein CD4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Southeast Asia T Cell Surface Glycoprotein CD4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Brazil T Cell Surface Glycoprotein CD4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Brazil T Cell Surface Glycoprotein CD4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Brazil T Cell Surface Glycoprotein CD4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Argentina T Cell Surface Glycoprotein CD4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Argentina T Cell Surface Glycoprotein CD4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Argentina T Cell Surface Glycoprotein CD4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Chile T Cell Surface Glycoprotein CD4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Chile T Cell Surface Glycoprotein CD4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Chile T Cell Surface Glycoprotein CD4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Colombia T Cell Surface Glycoprotein CD4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Colombia T Cell Surface Glycoprotein CD4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Colombia T Cell Surface Glycoprotein CD4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Peru T Cell Surface Glycoprotein CD4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Peru T Cell Surface Glycoprotein CD4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Peru T Cell Surface Glycoprotein CD4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Saudi Arabia T Cell Surface Glycoprotein CD4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Saudi Arabia T Cell Surface Glycoprotein CD4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Saudi Arabia T Cell Surface Glycoprotein CD4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Israel T Cell Surface Glycoprotein CD4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Israel Arabia T Cell Surface Glycoprotein CD4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Israel Arabia T Cell Surface Glycoprotein CD4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. UAE T Cell Surface Glycoprotein CD4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. UAE T Cell Surface Glycoprotein CD4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. UAE T Cell Surface Glycoprotein CD4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Turkey T Cell Surface Glycoprotein CD4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Turkey T Cell Surface Glycoprotein CD4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Turkey T Cell Surface Glycoprotein CD4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Iran T Cell Surface Glycoprotein CD4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Iran T Cell Surface Glycoprotein CD4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Iran T Cell Surface Glycoprotein CD4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Egypt T Cell Surface Glycoprotein CD4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 126. Egypt T Cell Surface Glycoprotein CD4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 127. Egypt T Cell Surface Glycoprotein CD4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 128. T Cell Surface Glycoprotein CD4 Value Chain Figure 129. Manufacturing Cost Structure Figure 130. T Cell Surface Glycoprotein CD4 Sales Mode & Process Figure 131. Direct Comparison with Distribution Share Figure 132. Distributors Profiles Figure 133. Years Considered Figure 134. Research Process Figure 135. Key Executives Interviewed

Scope & coverage.

Types
  • Forigerimod Acetate
  • Ibalizumab
  • HIV Vaccine 2
  • Others
Applications
  • HIV
  • GVHD
  • SARS
  • AIDS
  • Others
Companies covered
  • Sanofi
  • United Biomedical Inc
  • Bristol-Myers Squibb Co
  • TaiMed Biologics Inc
  • Immupharma Plc
  • Fountain Biopharma Inc
  • CEL-SCI Corp
  • Biotest AG

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global T Cell Surface Glycoprotein CD4 Sales Value (2021-2032)
  4. 1.2.2 Global T Cell Surface Glycoprotein CD4 Sales Volume (2021-2032)
  5. 1.2.3 Global T Cell Surface Glycoprotein CD4 Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 T Cell Surface Glycoprotein CD4 Market Dynamics
  1. 2.1 T Cell Surface Glycoprotein CD4 Industry Trends
  2. 2.2 T Cell Surface Glycoprotein CD4 Industry Drivers
  3. 2.3 T Cell Surface Glycoprotein CD4 Industry Opportunities and Challenges
  4. 2.4 T Cell Surface Glycoprotein CD4 Industry Restraints
3 T Cell Surface Glycoprotein CD4 Market by Company
  1. 3.1 Global T Cell Surface Glycoprotein CD4 Company Revenue Ranking in 2025
  2. 3.2 Global T Cell Surface Glycoprotein CD4 Revenue by Company (2021-2026)
  3. 3.3 Global T Cell Surface Glycoprotein CD4 Sales Volume by Company (2021-2026)
  4. 3.4 Global T Cell Surface Glycoprotein CD4 Average Price by Company (2021-2026)
  5. 3.5 Global T Cell Surface Glycoprotein CD4 Company Ranking (2024-2026)
  6. 3.6 Global T Cell Surface Glycoprotein CD4 Company Manufacturing Base and Headquarters
  7. 3.7 Global T Cell Surface Glycoprotein CD4 Company Product Type and Application
  8. 3.8 Global T Cell Surface Glycoprotein CD4 Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global T Cell Surface Glycoprotein CD4 Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 T Cell Surface Glycoprotein CD4 Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 T Cell Surface Glycoprotein CD4 Market by Type
  1. 4.1 T Cell Surface Glycoprotein CD4 Type Introduction
  2. 4.1.1 Forigerimod Acetate
  3. 4.1.2 Ibalizumab
  4. 4.1.3 HIV Vaccine 2
  5. 4.1.4 Others
  6. 4.2 Global T Cell Surface Glycoprotein CD4 Sales Volume by Type
  7. 4.2.1 Global T Cell Surface Glycoprotein CD4 Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global T Cell Surface Glycoprotein CD4 Sales Volume by Type (2021-2032)
  9. 4.2.3 Global T Cell Surface Glycoprotein CD4 Sales Volume Share by Type (2021-2032)
  10. 4.3 Global T Cell Surface Glycoprotein CD4 Sales Value by Type
  11. 4.3.1 Global T Cell Surface Glycoprotein CD4 Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global T Cell Surface Glycoprotein CD4 Sales Value by Type (2021-2032)
  13. 4.3.3 Global T Cell Surface Glycoprotein CD4 Sales Value Share by Type (2021-2032)
5 T Cell Surface Glycoprotein CD4 Market by Application
  1. 5.1 T Cell Surface Glycoprotein CD4 Application Introduction
  2. 5.1.1 HIV
  3. 5.1.2 GVHD
  4. 5.1.3 SARS
  5. 5.1.4 AIDS
  6. 5.1.5 Others
  7. 5.2 Global T Cell Surface Glycoprotein CD4 Sales Volume by Application
  8. 5.2.1 Global T Cell Surface Glycoprotein CD4 Sales Volume by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global T Cell Surface Glycoprotein CD4 Sales Volume by Application (2021-2032)
  10. 5.2.3 Global T Cell Surface Glycoprotein CD4 Sales Volume Share by Application (2021-2032)
  11. 5.3 Global T Cell Surface Glycoprotein CD4 Sales Value by Application
  12. 5.3.1 Global T Cell Surface Glycoprotein CD4 Sales Value by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global T Cell Surface Glycoprotein CD4 Sales Value by Application (2021-2032)
  14. 5.3.3 Global T Cell Surface Glycoprotein CD4 Sales Value Share by Application (2021-2032)
6 T Cell Surface Glycoprotein CD4 Regional Sales and Value Analysis
  1. 6.1 Global T Cell Surface Glycoprotein CD4 Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global T Cell Surface Glycoprotein CD4 Sales by Region (2021-2032)
  3. 6.2.1 Global T Cell Surface Glycoprotein CD4 Sales by Region: 2021-2026
  4. 6.2.2 Global T Cell Surface Glycoprotein CD4 Sales by Region (2027-2032)
  5. 6.3 Global T Cell Surface Glycoprotein CD4 Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global T Cell Surface Glycoprotein CD4 Sales Value by Region (2021-2032)
  7. 6.4.1 Global T Cell Surface Glycoprotein CD4 Sales Value by Region: 2021-2026
  8. 6.4.2 Global T Cell Surface Glycoprotein CD4 Sales Value by Region (2027-2032)
  9. 6.5 Global T Cell Surface Glycoprotein CD4 Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America T Cell Surface Glycoprotein CD4 Sales Value (2021-2032)
  12. 6.6.2 North America T Cell Surface Glycoprotein CD4 Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe T Cell Surface Glycoprotein CD4 Sales Value (2021-2032)
  15. 6.7.2 Europe T Cell Surface Glycoprotein CD4 Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific T Cell Surface Glycoprotein CD4 Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific T Cell Surface Glycoprotein CD4 Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America T Cell Surface Glycoprotein CD4 Sales Value (2021-2032)
  21. 6.9.2 South America T Cell Surface Glycoprotein CD4 Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa T Cell Surface Glycoprotein CD4 Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa T Cell Surface Glycoprotein CD4 Sales Value Share by Country, 2025 VS 2032
7 T Cell Surface Glycoprotein CD4 Country-level Sales and Value Analysis
  1. 7.1 Global T Cell Surface Glycoprotein CD4 Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global T Cell Surface Glycoprotein CD4 Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global T Cell Surface Glycoprotein CD4 Sales by Country (2021-2032)
  4. 7.3.1 Global T Cell Surface Glycoprotein CD4 Sales by Country (2021-2026)
  5. 7.3.2 Global T Cell Surface Glycoprotein CD4 Sales by Country (2027-2032)
  6. 7.4 Global T Cell Surface Glycoprotein CD4 Sales Value by Country (2021-2032)
  7. 7.4.1 Global T Cell Surface Glycoprotein CD4 Sales Value by Country (2021-2026)
  8. 7.4.2 Global T Cell Surface Glycoprotein CD4 Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA T Cell Surface Glycoprotein CD4 Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA T Cell Surface Glycoprotein CD4 Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA T Cell Surface Glycoprotein CD4 Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada T Cell Surface Glycoprotein CD4 Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada T Cell Surface Glycoprotein CD4 Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada T Cell Surface Glycoprotein CD4 Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico T Cell Surface Glycoprotein CD4 Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico T Cell Surface Glycoprotein CD4 Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico T Cell Surface Glycoprotein CD4 Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany T Cell Surface Glycoprotein CD4 Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany T Cell Surface Glycoprotein CD4 Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany T Cell Surface Glycoprotein CD4 Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France T Cell Surface Glycoprotein CD4 Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France T Cell Surface Glycoprotein CD4 Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France T Cell Surface Glycoprotein CD4 Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. T Cell Surface Glycoprotein CD4 Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. T Cell Surface Glycoprotein CD4 Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. T Cell Surface Glycoprotein CD4 Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy T Cell Surface Glycoprotein CD4 Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy T Cell Surface Glycoprotein CD4 Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy T Cell Surface Glycoprotein CD4 Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain T Cell Surface Glycoprotein CD4 Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain T Cell Surface Glycoprotein CD4 Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain T Cell Surface Glycoprotein CD4 Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia T Cell Surface Glycoprotein CD4 Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia T Cell Surface Glycoprotein CD4 Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia T Cell Surface Glycoprotein CD4 Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands T Cell Surface Glycoprotein CD4 Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands T Cell Surface Glycoprotein CD4 Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands T Cell Surface Glycoprotein CD4 Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries T Cell Surface Glycoprotein CD4 Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries T Cell Surface Glycoprotein CD4 Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries T Cell Surface Glycoprotein CD4 Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China T Cell Surface Glycoprotein CD4 Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China T Cell Surface Glycoprotein CD4 Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China T Cell Surface Glycoprotein CD4 Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan T Cell Surface Glycoprotein CD4 Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan T Cell Surface Glycoprotein CD4 Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan T Cell Surface Glycoprotein CD4 Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea T Cell Surface Glycoprotein CD4 Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea T Cell Surface Glycoprotein CD4 Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea T Cell Surface Glycoprotein CD4 Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India T Cell Surface Glycoprotein CD4 Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India T Cell Surface Glycoprotein CD4 Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India T Cell Surface Glycoprotein CD4 Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia T Cell Surface Glycoprotein CD4 Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia T Cell Surface Glycoprotein CD4 Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia T Cell Surface Glycoprotein CD4 Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia T Cell Surface Glycoprotein CD4 Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia T Cell Surface Glycoprotein CD4 Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia T Cell Surface Glycoprotein CD4 Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil T Cell Surface Glycoprotein CD4 Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil T Cell Surface Glycoprotein CD4 Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil T Cell Surface Glycoprotein CD4 Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina T Cell Surface Glycoprotein CD4 Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina T Cell Surface Glycoprotein CD4 Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina T Cell Surface Glycoprotein CD4 Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile T Cell Surface Glycoprotein CD4 Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile T Cell Surface Glycoprotein CD4 Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile T Cell Surface Glycoprotein CD4 Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia T Cell Surface Glycoprotein CD4 Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia T Cell Surface Glycoprotein CD4 Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia T Cell Surface Glycoprotein CD4 Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru T Cell Surface Glycoprotein CD4 Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru T Cell Surface Glycoprotein CD4 Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru T Cell Surface Glycoprotein CD4 Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia T Cell Surface Glycoprotein CD4 Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia T Cell Surface Glycoprotein CD4 Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia T Cell Surface Glycoprotein CD4 Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel T Cell Surface Glycoprotein CD4 Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel T Cell Surface Glycoprotein CD4 Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel T Cell Surface Glycoprotein CD4 Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE T Cell Surface Glycoprotein CD4 Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE T Cell Surface Glycoprotein CD4 Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE T Cell Surface Glycoprotein CD4 Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey T Cell Surface Glycoprotein CD4 Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey T Cell Surface Glycoprotein CD4 Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey T Cell Surface Glycoprotein CD4 Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran T Cell Surface Glycoprotein CD4 Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran T Cell Surface Glycoprotein CD4 Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran T Cell Surface Glycoprotein CD4 Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt T Cell Surface Glycoprotein CD4 Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt T Cell Surface Glycoprotein CD4 Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt T Cell Surface Glycoprotein CD4 Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Sanofi
  2. 8.1.1 Sanofi Company Information
  3. 8.1.2 Sanofi Business Overview
  4. 8.1.3 Sanofi T Cell Surface Glycoprotein CD4 Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Sanofi T Cell Surface Glycoprotein CD4 Product Portfolio
  6. 8.1.5 Sanofi Recent Developments
  7. 8.2 United Biomedical Inc
  8. 8.2.1 United Biomedical Inc Company Information
  9. 8.2.2 United Biomedical Inc Business Overview
  10. 8.2.3 United Biomedical Inc T Cell Surface Glycoprotein CD4 Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 United Biomedical Inc T Cell Surface Glycoprotein CD4 Product Portfolio
  12. 8.2.5 United Biomedical Inc Recent Developments
  13. 8.3 Bristol-Myers Squibb Co
  14. 8.3.1 Bristol-Myers Squibb Co Company Information
  15. 8.3.2 Bristol-Myers Squibb Co Business Overview
  16. 8.3.3 Bristol-Myers Squibb Co T Cell Surface Glycoprotein CD4 Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Bristol-Myers Squibb Co T Cell Surface Glycoprotein CD4 Product Portfolio
  18. 8.3.5 Bristol-Myers Squibb Co Recent Developments
  19. 8.4 TaiMed Biologics Inc
  20. 8.4.1 TaiMed Biologics Inc Company Information
  21. 8.4.2 TaiMed Biologics Inc Business Overview
  22. 8.4.3 TaiMed Biologics Inc T Cell Surface Glycoprotein CD4 Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 TaiMed Biologics Inc T Cell Surface Glycoprotein CD4 Product Portfolio
  24. 8.4.5 TaiMed Biologics Inc Recent Developments
  25. 8.5 Immupharma Plc
  26. 8.5.1 Immupharma Plc Company Information
  27. 8.5.2 Immupharma Plc Business Overview
  28. 8.5.3 Immupharma Plc T Cell Surface Glycoprotein CD4 Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Immupharma Plc T Cell Surface Glycoprotein CD4 Product Portfolio
  30. 8.5.5 Immupharma Plc Recent Developments
  31. 8.6 Fountain Biopharma Inc
  32. 8.6.1 Fountain Biopharma Inc Company Information
  33. 8.6.2 Fountain Biopharma Inc Business Overview
  34. 8.6.3 Fountain Biopharma Inc T Cell Surface Glycoprotein CD4 Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Fountain Biopharma Inc T Cell Surface Glycoprotein CD4 Product Portfolio
  36. 8.6.5 Fountain Biopharma Inc Recent Developments
  37. 8.7 CEL-SCI Corp
  38. 8.7.1 CEL-SCI Corp Company Information
  39. 8.7.2 CEL-SCI Corp Business Overview
  40. 8.7.3 CEL-SCI Corp T Cell Surface Glycoprotein CD4 Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 CEL-SCI Corp T Cell Surface Glycoprotein CD4 Product Portfolio
  42. 8.7.5 CEL-SCI Corp Recent Developments
  43. 8.8 Biotest AG
  44. 8.8.1 Biotest AG Company Information
  45. 8.8.2 Biotest AG Business Overview
  46. 8.8.3 Biotest AG T Cell Surface Glycoprotein CD4 Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Biotest AG T Cell Surface Glycoprotein CD4 Product Portfolio
  48. 8.8.5 Biotest AG Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 T Cell Surface Glycoprotein CD4 Value Chain Analysis
  2. 9.1.1 T Cell Surface Glycoprotein CD4 Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 T Cell Surface Glycoprotein CD4 Sales Mode & Process
  6. 9.2 T Cell Surface Glycoprotein CD4 Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 T Cell Surface Glycoprotein CD4 Distributors
  9. 9.2.3 T Cell Surface Glycoprotein CD4 Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst